Target intelligence / Profile preview

Porin A (PorA) and associated outer membrane vesicle proteins of Neisseria meningitidis serogroup B (PorA/OMV)

Target
PorA/OMV
Molecular classification
Porin, Outer membrane protein, Bacterial antigen
01

Overview

Porin A (PorA) is a major class 1 outer membrane protein of Neisseria meningitidis serogroup B that functions as a cation-selective channel, facilitating the transport of small nutrients across the bacterial cell wall [1]. In vaccine pharmacology, PorA is typically delivered within Outer Membrane Vesicles (OMVs), which are spherical blebs released from the bacterial surface that contain a complex array of proteins and lipids [2]. These OMV-based antigens are critical for Neisseria meningitidis serogroup B prevention because the bacterium's polysaccharide capsule is poorly immunogenic and mimics human neural cell adhesion molecules, making protein-based targets essential for vaccine efficacy [3]. Vaccines targeting PorA and OMV proteins work by eliciting serum bactericidal antibodies that activate the host complement system to lyse the bacteria [4]. However, the high degree of sequence variability in the PorA surface loops necessitates the use of specific OMV strains or multi-component formulations to achieve broad protection against diverse meningococcal isolates [5]. The inclusion of OMVs in vaccines like Bexsero provides both a delivery system for PorA and an intrinsic adjuvant effect through residual bacterial components, though this can also contribute to increased reactogenicity in clinical settings [2, 5].

Other names
Porin AClass 1 outer membrane proteinOuter membrane vesiclesMenB OMVPorAMeningococcal outer membrane vesicle proteins
02

Mechanism of action

Induction of active immunity through the production of serum bactericidal antibodies that facilitate complement-mediated lysis of Neisseria meningitidis [4].

03

Biological functions

Nutrient transportMembrane integrityImmune response inductionBacterial adhesion
04

Disease associations

Meningococcal meningitisMeningococcemiaInfection
05

Safety considerations

Antigenic variation leading to limited strain-specific immunityPyrogenicity due to residual lipooligosaccharide (LOS)High rate of systemic reactogenicity (e.g., fever) in infantsInjection site reactions
06

Interacting drugs

Meningococcal group B vaccine (Bexsero)

3 more in the full profile.

07

Biomarkers

Serum bactericidal activity (SBA) titerAnti-PorA IgG concentration

Beyond the preview

Go deeper on Porin A (PorA) and associated outer membrane vesicle proteins of Neisseria meningitidis serogroup B (PorA/OMV).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Porin A (PorA) and associated outer membrane vesicle proteins of Neisseria meningitidis serogroup B (PorA/OMV).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call